AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 121 min read$ALHC

KAO JOHN E sold $6.1M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at an average of $20.36 ($19.65–$20.60, $6.07M total) across 2 trades on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Jun 12, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$6.07M is newly reported; the 10b5-1 designation reduces interpretive value regarding near-term fundamentals.

02

Market read

Provides a fresh, company-specific insider selling datapoint that can influence short-term sentiment but lacks fundamental catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance/clinical/regulatory updates, the signal is typically weak.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed June 12 (covering June 10 sales)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

CEO KAO JOHN E sold $6.07M of Alignment Healthcare shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is new and company-specific, but the transaction is explicitly under a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

Sector

No direct sector read-through; this is a single-company insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Alignment Healthcare, Inc.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • insider
    KAO JOHN E

    Chief Executive Officer and director who sold shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan noted as Yes, indicating scheduled selling.

Read at source← All news

Related articles

AUG 7
$ALHCMed

Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending?

Alignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.

finance.yahoo.com6 min
AUG 3
$ALHCMed

Kaplan Fox Reminds Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors of an Investigation Into Potential Securities Law Violations

Kaplan Fox said a former Alignment Healthcare executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the July 8, 2026 report, ALHC shares fell $4.02, or 16.7%, to close at $20.03, according to the article.

theglobeandmail.com3 min
JUL 31
$ALHCMed

Alignment Healthcare (ALHC) Stock Trades Down, Here Is Why

Alignment Healthcare (ALHC) shares fell 14.8% after the company said it will reinvest profits, lowering expected second-half 2026 earnings. On its Q2 2026 call, management raised full-year revenue guidance but expects only about 30% of adjusted EBITDA in the second half, versus 40% a year earlier, due to investment timing.

financialcontent.com3 min
JUL 31
$ALHCHighAI 9/10

Alignment Healthcare (ALHC) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Executive Chairman and Chief Executive Officer - John E. Kao Chief Financial Officer - James Head TAKEAWAYS Health Plan Membership -- 294,000 members, representing 31% growth year over year. Total Revenue -- $1.3 billion, an increase of 32% year over year driven by membership growth. Adjusted MBR -- 86.3%, an improvement of 40 basis points year over year and the lowest since the company went public.

fool.com6 min
JUL 31
$ALHCHighAI 9/10

Alignment Misses Q2 EPS Estimates

Stock falls 12% in after-hours trading Shares in Alignment Healthcare fell 12% in after-hours trading after reporting second quarter results. Orange-based Alignment, a Medicare Advantage provider for seniors, reported earnings per share (EPS) of 17 cents, missing the 20-cent consensus estimate, according to the TheFly.com. The company’s third-quarter revenue outlook of $1.3 billion to $1.32 billion also came in at the low end of Wall Street estimates.

ocbj.com2 min
JUL 30
$ALHCMedAI 8/10

Alignment Healthcare (NASDAQ:ALHC) Beats Q2 CY2026 Sales Expectations But Stock Drops

Health insurance company Alignment Healthcare (NASDAQ: ALHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.6% year on year to $1.34 billion. The company expects next quarter’s revenue to be around $1.31 billion, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 29.8% above analysts’ consensus estimates. Is now the time to buy Alignment Healthcare? Find out by accessing our full research report, it’s free.

financialcontent.com4 min